So recently one of the planet's top sepsis experts ( top .0029% in some circles ) declared that >70% of sepsis patients with high endotoxin levels were "culture negative"...

In the Euphrates phase 3 trial we "knocked it out of the park" with this important subset of per protocol patients.  We achieved a 21% absolute benefit or ~ double the 10.7% achieved on the 194 patients we applied to the current phase 3B trial...

My question would be why only 13% of patients ( 59 patients ) in the phase 3 Euphrates were "culture negative".  ALL our patients had high endotoxin ( actually too high in many cases )  How does the recent number of >70% relate to the random selection and curiously low 13% in the phase 3 trial?

TIA for meaningful and thoughtful responses